by The biopharma buffer market plays a crucial role in biopharmaceutical production as buffer solutions are used to control and maintain the pH of biologics during various stages of production including fermentation, purification, formulation, and storage. Commonly used buffers include phosphate buffers, Tris buffers, and acetate buffers. Pharmaceutical buffer solutions help stabilize pH and ensure product efficacy and safety. The global biopharma buffer market is driven by the growth of the biopharmaceutical industry and rising production of biosimilars. With the expiry of patents of blockbuster biologics, biosimilar manufacturers are developing affordably-priced follow-on biologics. This is expected to significantly propel the demand for biopharma buffer solutions in coming years.
The global biopharma buffer market is estimated to be valued at US$ 3.68 Bn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Growing Biosimilar Production: Increasing patent expiration of major blockbuster biologics and the development of affordable biosimilars is one of the major factors driving the growth of the global biopharma buffer market. For example, the patent expiration of biologics such as Humira, Avastin, Rituxan and Herceptin provides opportunities for biosimilar manufacturers to develop follow-on versions at much lower costs. This is expected to further boost research and manufacturing activities in the biosimilars segment, fueling the demand for biopharma buffer solutions.
Regulatory Approvals: Stringent regulatory guidelines for buffer quality by regulatory agencies such as FDA and EMA has prompted biopharma companies to adhere to recommended practices in using buffer solutions. This ensures product safety and efficiency. Furthermore, regulatory approvals of biosimilars in developed markets such as US and EU5 nations are encouraging biosimilar manufacturers worldwide, thereby augmenting consumption of biopharma buffers.
Segment Analysis
The biopharma buffer market is dominated by the pharmaceutical buffer segment which holds around 65% of the total market share. Pharmaceutical buffers are used extensively in the production of vaccines, biologics and other pharmaceutical products. They help maintain the pH balance during various stages of drug manufacturing and packaging. The wide application of buffers in biologics and vaccine production has boosted the growth of this segment over other segments.
PEST Analysis
Political: Stringent regulatory norms regarding drug development and manufacturing have increased the quality standards and demand for high purity buffers from regulatory bodies.
Economic: Growing pharmaceutical R&D expenditure and rise of biologics over small molecule drugs is positively impacting the market growth.
Social: Increasing prevalence of chronic diseases and demand for affordable healthcare is augmenting the pharmaceutical production and research activities globally.
Technological: Advancements in continuous manufacturing technologies and single-use bioreactor systems have increased the application scope of biopharma buffers.
Key Takeaways
The Global Biopharma Buffer Market Size is expected to witness high growth over the forecast period. The global biopharma buffer market is estimated to be valued at US$ 3.68 Bn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030.
North America currently dominates the market owing to presence of major pharmaceutical companies and growing biosimilars industry in the region. The rising outsourcing of biopharmaceutical manufacturing to Asian contract manufacturing organizations is fueling the market growth in Asia Pacific. The Europe market is growing steadily supported by presence of strong biotech industry and adoption of advanced technologies by CMOs and CROs.
Key players
Key players operating in the biopharma buffer market are Avantor, Inc., Alfa Aesar (Thermo Fisher), Merck, Lonza, Bio-Rad Laboratories, Inc., Promega Corporation. These major players cater to over 60% of global biopharma buffer demand.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
